Marc Martinell Pedemonte

This inventor holds 19 USPTO granted patents and 13 published patent applications, plus 4 CIPO patents and 11 EPO patents, primarily in LSD1 Inhibitors. Top assignees: Oryzon Genomics S.a., Minoryx Therapeutics S.l.. Active years: 2015-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Marc Martinell Pedemonte. Retrieved from https://idiyas.com/inventor/marc-martinell-pedemonte

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 19 (Patent Applications = 13)

% Patents Active = 78.9

CIPO Patents = 4 (Patent Applications = 5)

EPO Patents = 11 (Patent Applications = 24)

Average Co-Inventor Count = 4.8

ph-index = 8

Forward Citations = 132(Granted Patents)

Company Filing History:

Minoryx Therapeutics S.l.

patents

Years Active: 2015-2026

Loading Chart...

Areas of Expertise:

LSD1 Inhibitors

Thiazolidinedione Derivatives

Cyclopropylamine Compounds

Arylcyclopropylamine

Demethylase Inhibitors

Beta Galactosidase

Mitochondrial Diseases

Nonalcoholic Fatty Liver Disease

Central Nervous System Disorders

Myeloproliferative Disorders

Therapeutic Uses

Isoquinoline Compounds

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12673048 - Method of administering a therapeutically effective amount of 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione (2026-07-07),

2. 11957670 - 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione and its salts for use in the treatment of mitochondrial diseases (2024-04-16),

3. 11938122 - 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3- thiazolidine-2,4-dione for treating nonalcoholic fatty liver disease (2024-03-26),

4. 11440898 - Isoquinoline compounds, methods for their preparation, and therapeutic uses thereof in conditions associated with the alteration of the activity of beta galactosidase (2022-09-13),

5. 10329256 - (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors (2019-06-25),

6. 10233178 - Arylcyclopropylamine based demethylase inhibitors of LSD1 and their medical use (2019-03-19),

7. 10214477 - (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors (2019-02-26),

8. 10179126 - 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders (2019-01-15),

9. 9944601 - (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors (2018-04-17),

10. 9908859 - Lysine demethylase inhibitors for myeloproliferative disorders (2018-03-06),

11. 9782395 - 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders (2017-10-10),

12. 9708309 - Arylcyclopropylamine based demethylase inhibitors of LSD1 and their medical use (2017-07-18),

13. 9676701 - Cyclopropylamine derivatives useful as LSD1 inhibitors (2017-06-13),

14. 9670136 - (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors (2017-06-06),

15. 9487512 - (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors (2016-11-08),

Title: Marc Martinell Pedemonte - Innovative Inventor from Barcelona

Introduction: Marc Martinell Pedemonte is a renowned inventor hailing from Barcelona, Spain, known for his groundbreaking contributions to various fields through his innovative creations.

Latest Patents: Marc Martinell Pedemonte holds several patents in the areas of technology, healthcare, and sustainable energy, showcasing his diverse range of interests and expertise.

Career Highlights: With a successful career spanning over two decades, Marc Martinell Pedemonte has established himself as a pioneer in the world of inventions, with numerous accolades and recognitions for his impactful work.

Collaborations: Throughout his career, Marc Martinell Pedemonte has collaborated with leading research institutions, universities, and companies worldwide, fostering a culture of innovation and knowledge sharing.

Conclusion: Marc Martinell Pedemonte's passion for innovation and his relentless pursuit of excellence continue to inspire aspiring inventors and shape the future of technology and beyond.

Profile summary based on public USPTO records.